GlobeNewswire

Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activités
13/11/2026
.HEAL-101 a atteint jusqu'à 70 % d'édition in vivo d'APOC3, avec une activité limitée au foie, et a confirmé une réduction de 76 % des triglycérides dans des modèles murins (ESGCT 2026) ; lancement de l'essai de phase 1 [...]
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
13/11/2026
.HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity and confirmed 76% triglyceride reduction in murine models (ESGCT 2026); Phase 1 IIT in China on track for initiation, with preliminary [...]
Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
13/11/2026
- FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and a future NDA submission - - U.S. patent office has granted priority examination (Track 1) for the [...]
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
12/11/2026
Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400 Continued enrollment in first-in-human Phase 1 clinical [...]
Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
12/11/2026
REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita ® participants retained approximately 80% of GLP-1-induced weight loss versus 67% for sham Planned FDA [...]
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance Shared new advances in RNA therapeutic manufacturing at TIDES Europe Entered into a $60 million term loan [...]
Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
12/11/2026
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027 Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million [...]
CapsoVision Reports Third Quarter 2026 Financial Results
12/11/2026
SARATOGA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
12/11/2026
– Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 – – Advanced three [...]
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
12/11/2026
Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, [...]
Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus Initiated Phase 2 studies with [...]
LifeMD Reports Third Quarter 2026 Results
12/11/2026
Third quarter 2026 revenue of $44.6 million; adjusted EBITDA loss of approximately $0.4 million, within the Company’s guidance range of negative $1 million to positive $2 million. Adjusted EBITDA improved approximately [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026
12/11/2026
PORTLAND, Maine, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
12/11/2026
The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines associated with certain assay refinement, the [...]
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
12/11/2026
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical [...]
Solésence Reports Record Third Quarter 2026 Financial Results
12/11/2026
Third quarter revenue increases 38% year-over-year to $20.2 million Third quarter net income of $3.7 million highest in company’s history Company to host conference call today at 4:00 p.m. CT, 5:00 p.m. ET ROMEOVILLE, [...]
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
12/11/2026
– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response [...]
Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
12/11/2026
Azora Therapeutics commenced trading on Nasdaq as “AZR” New executive team and Board of Directors appointed AT177 IND submission and Phase 1a initiation on track for the first half of 2027 LOS ANGELES, Nov. 12, 2026 ( [...]
Jushi Holdings Inc. Announces Opening of Relocated Beyond Hello™ Dispensary in Hamburg, Pennsylvania
12/11/2026
BOCA RATON, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSH ) , a vertically integrated, multi-state cannabis operator, today announced the opening of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum